Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
A biomarker is a marker which can be precisely measured to indicate conventional biological function, pathogenic pathways, or drug response to therapeutic drug intervention. Biological markers are typically designed at the molecular level. Biological markers are found in a variety of bodily functions, including disease diagnosis and prediction, treatment response prediction and calculation, and safety assessment. These biomarkers are developed and approved for use in drug development and to support drug product approval.
Tumor biomarkers are biomarkers that are used to treat tumors. They aid in making precise diagnoses. Cancer biomarkers can also distinguish whether tumors are primary or metastatic in nature. A cancer biomarker is frequently a molecule produced by a tumor or a specific body response to the presence of a tumor. Biomarkers for human prostate, breast, ovarian, and lung cancers, as well as heart disease, arthritis, asthma, and cystic fibrosis, are investigated. Biological markers can help determine the accuracy of a diagnosis and are frequently linked to other investigations to rule out cancer.
Clinical support detection phases and translated biomarkers are inclined to identify the effect of compound on organs or tissues before the clinical effect is exhibited. It is frequently divided into three categories: biomarkers for disease, target biomarkers, and mechanism biomarkers. A biomarker for translation is defined by whether it is frequently visible, quantifiable, and eventually trained or verified.
Cardiovascular disease (CVD) is still the most prominent concern in the world. The detection of traditional risk factors such as age, hypertension, diabetes, and smoking improved CVD first-line prevention. Heart indicators are biomarkers that are measured to assess heart function. They're frequently studied in the context of a myocardial infarction, but other factors can cause an increase in the level of the gut's marker. Cardiac biomarkers are substances that are released into the bloodstream when the gut is injured or stretched. A heart marker is used to identify and stratify patients with pain and suspected acute coronary syndrome (ACS). Enzymes, hormones, and proteins are examples of these markers
Molecular biomarkers are defined as biomarkers that will be discovered through basic and widely accepted proposals such as genomics and proteomics. This apart from genomics and proteomics platforms, biomarker assessment techniques such as metabolomics, lipidomic, and glycemic are commonly used as biomarker recognition techniques. Pathological biomarkers, macromolecule biomarkers, Insilco biomarkers, glycoprotein biomarkers, and bio-imaging markers are the different types of molecular biomarkers based on their structure and function. These biomarkers are frequently tested for biological fluids that are not abnormally composed, such as blood or serum
Drug discovery using biomarkers is used solely for patient diagnosis and monitoring in clinical trials. Biological markers increase the success rates of drug advancement programmers, hastening the availability of advanced therapies. Biomarker enhancement could be a multi-step and repetitive process that begins with the discovery of biomarkers in infectious diseases. An analytical authentication phase of biomarker development, pharmacogenomics, functional proteomics, biological analytical validation method, and pharmacokinetic models will be created during this session.
Biomarkers are crucial in the detection and management of breast cancer patients. As a result, BRCA1/2 mutation testing is used to assess risk in families with a high risk of breast and ovarian cancer. Following a breast cancer diagnosis, multi-analyte profiles such as uPA/PAI-1 or Oncotype DX may be used to determine prognosis and identify lymph node-negative patients who may be spared from adjuvant chemotherapy. Other -gene tests, such as the PAM50 ROR, Breast Cancer Index, and Endo Predict, have been shown to predict late recurrences and may be useful in selecting patients for extended hormone therapy. Burden of disease biomarkers
Blood biomarkers are involved in auto immune dysfunction of the central nervous system. Biomarkers are not meeting a significant need in assessing prediction, response to treatment, or potential complications in treatment. There are several constraints in the process of discovering and validating an honest biomarker, such as the pathophysiological complexity of MS and thus the technical difficulties of establishing a global standard of methods for selecting, processing, and maintaining biological trials.
Biological markers are important tools for drug development and research. Biological markers were recognised for making the drug development process more efficient and have become an important part of pharmacology and drug research. Several biomarkers are expected to be transferred to the clinical laboratory in the future. Biological markers show drug-dose-response relationships between changes in biomarker, onset of injury, and severity of injury as the injury evolves.
Biomarkers related to genomics measure changes in the amount or nature of nucleic acids. DNA-based biomarkers include copy number variation, mutations, and epigenetic changes. Quantification of mRNA, microRNA, and long non-coding RNA expression are examples of biological markers that support RNA expression. The serum proteome is made up of several small peptides that are produced as a result of various cellular activities. Proteomics is widely used in a variety of medical fields, including drug development and biomarker discovery. Proteomics has a broad impact on identifying biomarkers and revolutionizing the drug development process by synchronizing with other advanced genomics and bioinformatics techniques
Neurology is concerned with the diagnosis and treatment of central and peripheral systema nervosum disease, and it is one of the standard constraints in which personalised medicine has become an important part of clinical trials. Various issues in neurology should be investigated, including individualised medicine and diagnostic, prognostic, and predictive biomarkers. The importance of biomarkers and personalised medicine in neuro-oncology is growing. Several areas of neurology should discuss the current state of data.
The use of biomarkers and diagnostic evaluations is expanding, resulting in the introduction of simpler sensitivity tests. These tests are effective clinical care tools for a variety of therapeutic areas, including oncology, immunology, cardiology, and endocrinology. Recent biosensor advancements for the discovery of biomarkers in cancer therapy
Biomarkers in health and disorders are concerned about promising findings from a pediatric autism spectrum disorder survey. The researchers wanted to use cerebral resonance imaging (MRI) to compare cortical and cerebrovascular development in infants aged 6-12 months who were at risk of ASD with ASD affected children who would have ASD for up to 24 months. While this study needs to be replicated in a larger group of 15 of 106 high-risk subjects who eventually developed ASD, it does highlight the significant and unmet medical need for biomarkers for neural and psychiatric disorders. Co-morbidity with other psychiatric disorders is also uncommon, leading to a dizzying array of possible diagnoses. Clinical biomarkers can assist in overcoming these limitations
Biomarkers are important in the prediction and identification of a variety of cardiovascular and neurological diseases. With advances in biomarkers and various diagnostic processes and imaging technologies, diseases that are lethal with age can now be treated and diagnosed easily. Cardiac and neuro-biomarkers have revolutionised disease diagnosis and prediction. These biomarkers are also used to diagnose a variety of non-cancerous diseases. Alzheimer's disease, disorder, Huntington's chorea, condition, and diabetes are a few examples.
In contrast to molecular biomarkers, bio-imaging markers allow for earlier disease recognition, which optimises translational research in drug discovery and researchers under cancer images in the market. X-ray, computerised tomography (CT), positron emission tomography (PET), single emission computerised tomography (SPECT), and resonance imaging are a few examples of image-based biomarkers (MRI).
Digital biomarkers are frequently mentioned as a digital device diagnosis that will provide clinical data as significant digital data. It can forecast the physiological and behavioural findings of a patient's condition, determining what is a healthy normal stage of disease and future health outcomes. It is commonly referred to as a self-diagnostic device because it is wearable, portable, transplantable, and digestible depending on the diagnosis and condition
Biological or genetic tests are a class of tests that look for molecular signs of disease so that doctors can treat them effectively. Biological markers, which serve as the foundation for accurate oncology, are critical in the organization of esophageal, breast, and lung cancers. Testing practices are rigorously scrutinized, with implications for pathologists, oncologists, and patients. Biomarker testing advances are mostly concentrated in the fields of cancer, which are divided into chromosomes, gene tests, and biochemical tests. Micro-RNA biomarkers and a number of other clinical biomarkers discovered in the most recent study have paved the way for wider biomarker testing
Biomarkers are commonly used to detect the occurrence of a disease or condition and to identify entities with a disease subtype. Diagnostic biomarkers are in agreement with the occurrence of specialized cancer examination programme (cellular and molecular pathology). Therapeutic biomarkers have a large impact on a wide range of therapeutic medications for disorder, rarity, communicable disease, and genetic disease.
Biobanks are collections of human biological tissue specimens and health-related data. Biobank research aims to provide new insights into the genetic component of disease, eventually leading to a more personalized approach to healthcare. And the importance of biobanking is outlined below.